TP53 and acute myeloid leukemia: Furthermore, 20% of patients had RUNX1-mutated AML, 15% ASXL1-mutated AML, and 13% TP53-mutated AML, all markers that are categorized within the adverse-risk group in the 2017 ELN risk stratification [34]; in addition, 25% of patients had IDH1/IDH2-mutated AML.